The Thalassaemia International Federation has participated in the 6th Annual CEETII Patient Advocacy Group Forum 2020 held on 3 November 2020, organised by Bristol Myers Squibb (BMS).
The Forum brought together patient advocates from Central and Eastern Europe, India, Russia and India to discuss patient needs, engagement, support and awareness in relation to existing and new challenges in diagnostics, treatment and R&D.
The theme of this year’s meeting was IMPACT – on patients, on innovation, on awareness and on access to care. In this context, Mr George Constantinou, TIF Board Member and Expert Patient, represented TIF through a presentation focusing on the unmet needs of thalassaemia patients, and highlighting the ways that the Federation works towards alleviating them and thus improving the lives of patients globally.
Moreover, Mr Constantinou stressed the importance of patient involvement in decision-making bodies, especially in the case of life-long chronic conditions, such as thalassaemia. The meeting was also attended by Dr Androulla Eleftheriou, TIF Executive Director, and Ms Lily Cannon, TIF Operations Manager.